C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Sponsor
Atea Pharmaceuticals, Inc.
Study ID
NCT07037277
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • HEPATITIS C VIRUS CHRONIC INFECTION
  • Hepatitis C
  • Hepatitis C Virus Infection
  • Hepatitis C, Chronic

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Bemnifosbuvir-Ruzasvir — DRUG
    BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)
  • Sofosbuvir-Velpatasvir — DRUG
    SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks

Study Details

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Key Dates

Start date
Jun 2, 2025
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Mar 31, 2027

Study Design

Enrollment
880 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Bemnifosbuvir - Ruzasvir (BEM/RZR)
  • Active Comparator: Sofosbuvir-Velpatasvir (SOF/VEL)

Primary Outcome Measure

Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24 [ Time Frame: Day 1 through Week 24 ]

Central Contacts

Related Studies